. . . . . . "Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain."@en . . . . " "@en . . "# Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US: The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005 Jan;16(1):1-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15650539 # Melzer C, Richter C, Rogalla P, Borges AC, Theres H, Baumann G, Laule M: Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004 Aug;18(1):47-50. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/15744554 # Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E: Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul;150(1):79-88. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16084152 # De Luca G, Suryapranata H, Chiariello M: Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary. Evid Based Cardiovasc Med. 2005 Dec;9(4):284-7. Epub 2005 Nov 2. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16380055 # : Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16488800"@en . . "191588-94-0"@en . . "Tenecteplase"@en . "1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo)"@en . "Humans and other mammals"@en . . "tPA"@en . "* 99 - 119 mL/min [acute myocardial infarction patients]"@en . . "t-plasminogen activator"@en . . "Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. "@en . . . "approved"@en . "For treatment of myocardial infarction and lysis of intracoronary emboli"@en . "t- PA"@en . . . . . . . "Tissue-type plasminogen activator precursor"@en . . . . .